RNS Number : 6377L MaxCyte, Inc. 14 September 2021 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2021 GAITHERSBURG, MD , September 13, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on
GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 8949K MaxCyte, Inc. 06 September 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Issue of Equity Increase to Block Listing Block Listing Return and Total Voting Rights GAITHERSBURG, MD , September 6, 2021 - MaxCyte, Inc.
RNS Number : 5833K MaxCyte, Inc. 02 September 2021 MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021 GAITHERSBURG, MD , September 02, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell
GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S.
RNS Number : 0791I MaxCyte, Inc. 10 August 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options Gaithersburg, Maryland - 10 August 2021 : MaxCyte (Nasdaq: MXCT) (LSE: MXCT, MXCN) , a leading provider of cell-engineering
Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hypoimmune cell therapy programs GAITHERSBURG, Md. , Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc.
RNS Number : 9261H MaxCyte, Inc. 09 August 2021 MaxCyte Signs Clinical and Commercial License with Sana Biotechnology Agreement represents MaxCyte's 14 th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform in conjunction
RNS Number : 7572H MaxCyte, Inc. 05 August 2021 Amendments to Bylaws GAITHERSBURG, MD , August 5, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading provider of cell-engineering platform technologies, announces that it has filed amended
RNS Number : 4604H MaxCyte, Inc. 03 August 2021 MaxCyte Announces Closing of Offering and Resulting Total Voting Rights This announcement contains inside information GAITHERSBURG, MD , August 3, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company
